AIDS Treatment Update, No. 44, August 1996
Edward King
Several studies presented ways in which people who suffer allergic reactions to Septrin can be desensitised, enabling many to take the drug without further problems. In one study, Septrin was started at a very low dose and gradually increased, alongside a gradually reducing dose of steroids to minimise the allergy, enabling nearly four out of five previously allergic people to tolerate Septrin (Tu.B.414). However, the design of this study means that this is a best-case estimate of the effectiveness of desensitisation.
An American study found that among people who are taking PCP prophylaxis, the risk of developing PCP was reduced even further if they were also receiving the drug azithromycin to prevent MAI, rather than the alternative MAI prophylactic drug rifabutin (Tu.B.410). In the USA, azithromycin was licensed for MAI prophylaxis in June (see AIDS Treatment Update issue 43).
960810
ATU4414
Copyright © 1996 - AIDS Treatment Update. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. NAM Publications 16a Clapham Common Southside, London, England SW4 7AB; TEL: 01-71-627-3200 (from outside the UK: +44-171-627-3200); FAX: 01-71-627-3101 (from outside the UK: +44=171-627-3101) info@nam.org.uk http://www.nam.org.uk